bioRxivMicrobiologyPreprint
CD81 is an Ebola virus inhibiting factor that is antagonized by GP and VP40
Dan Hu, Elena HagelaueriD, Lisa WendtiD, Matteo BossoiD, Maximilian BunziD, Julia Kammerloher, Jasmin S. KutteriD, Johannes BrandiiD, Lina WiderspickiD, Thomas HoeneniD, Michael SchindleriD
Abstract
Viruses manipulate the host cell membrane of infected cells for evasion of antiviral immunity, prevention of superinfection and optimization of viral replication and spread. The Ebola virus glycoprotein (EBOV GP) mediates virus entry, but is also known as important factor for subversion of the hosts antiviral immune response. We characterized the dysregulation of cell surface-residing proteins by EBOV GP and found that among several membrane proteins GP interferes with the tetraspanins CD81, CD63 and CD9. This was a conserved function of several filoviral GPs and not observable for viral glycoproteins of other virus families. While CD63 and CD9 were largely dispensable for EBOV replication, CD81 suppressed virus-like particle entry and replication at multiple steps. This phenotype might be explainable by sustained suppression of NF{kappa}B by CD81, that is otherwise activated by VP40 and EBOV trVLP replication. We further demonstrate that not only GP but also VP40 interferes with CD81 functionality and that antibody-mediated clustering of CD81 suppresses EBOV infection. Altogether, the tetraspanin CD81 emerges as druggable NF{kappa}B and EBOV-inhibiting factor, supporting an important role of NF{kappa}B in EBOV replication and potentially virus-induced immunopathogenesis. HighlightsO_LIEBOV GP and VP40 interfere with CD81 cell surface expression C_LIO_LICD81 suppresses NF{kappa}B signaling which is activated by VP40 C_LIO_LICD81 restricts EBOV VLP uptake and replication C_LIO_LITargeting CD81 by a crosslinking antibody inhibits EBOV infection C_LI
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Activating NK- receptors, homing selectins and inhibitory Siglecs recognize EBOLA-GP and HPV-L1NK
M. Jarahian, K. Marstaller, … C. Watzl·bioRxiv·Jul 24, 2020
- Ebola virus glycoprotein domains associated with protective efficacy
B. Bhatia, W. Furuyama, … A. Marzi·bioRxiv·May 22, 2021
- FAM134B isoform 2/RETREG1-2 defines a calnexin-TOLLIP-coupled ER-phagy pathway that restricts Ebola virus glycoprotein and is antagonized by VP40 through macro-autophagy
Jing Zhang, Tao Wang, … Yong‐Hui Zheng·bioRxiv·Apr 2, 2026
- TIM-1 SERVES AS A NONREDUNDANT RECEPTOR FOR EBOLA VIRUS, ENHANCING VIREMIA AND PATHOGENESIS
B. Brunton, K. Rogers, … W. Maury·bioRxiv·Nov 8, 2018
- Direct intracellular visualization of Ebola virus-receptor interaction by in situ proximity ligation
E. Mittler, T. P. Alkutkar, … K. Chandran·bioRxiv·May 5, 2020
- Novel Mechanism of Inflammatory Activation by Ebola Virus Matrix Protein Linked to the Ebolavirus Virulence
Satoko Yamaoka, Zeineb Mhamdi, … Hideki Ebihara·Proceedings of the National Academy of SciencesPeer-reviewed·Dec 29, 2025